Status:
COMPLETED
First-In-Human PainCart Study for STR-324
Lead Sponsor:
Stragen France
Conditions:
Pain
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
This is an interventional, first-in-man study, double-blind, placebo-controlled, two-part, ascending doses study to investigate the safety, tolerability and efficacy of STR-324 infusions in healthy vo...
Detailed Description
Part I : ascending doses of short lasting infusion Part II : ascending doses of long lasting infusion
Eligibility Criteria
Inclusion
- Signed informed consent prior to any study-mandated procedure
- Healthy male subjects, 18 to 45 years of age, inclusive at screening.
- Body mass index (BMI) between 18 and 30 kg/m2, inclusive at screening, and with a minimum weight of 50 kg.
- All males must practice effective contraception during the study and be willing and able to continue contraception for at least 90 days after their last dose of study treatment.
- Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions.
Exclusion
- Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator
- Subject with clinically significant abnormalities in blood pressure, heart rate, ECG recording and laboratory parameters
- Abnormal renal function (eGFR (MDRD) \< 60 mL/min/1.73m2).
- Previous history of seizures or epilepsy.
- Acute disease state (e.g. nausea, vomiting, fever, or diarrhea) within 7 days before the first study day.
- Positive Hepatitis B surface antigen (HBsAg), Hepatitis B antibodies, Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab)
- Use of any medications (prescription or over-the-counter \[OTC\]), within 14 days of study drug administration, or less than 5 half-lives (whichever is longer).
- Use of any vitamin, mineral, herbal, and dietary supplements within 7 days of study drug administration, or less than 5 half-lives (whichever is longer).
- Participation in an investigational drug or device study within 3 months prior to first dosing.
- History of abuse of addictive substances or current use of substances (alcohol, illegal substances)
- Positive test for drugs of abuse or alcohol breath test at screening or pre-dose.
- Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (non-active hay fever is acceptable).
- Loss or donation of blood over 500 mL within three months prior to screening
- Any current, clinically significant, known medical condition in particular any existing conditions that would affect sensitivity to cold or pain
Key Trial Info
Start Date :
February 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 7 2018
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT03430232
Start Date
February 20 2018
End Date
November 7 2018
Last Update
December 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHDR
Leiden, Netherlands, 2333